(¹⁴C Study ) This is a Phase 1 study looking at how a new research medication called VT3989 moves through the body after a single oral dose that contains a small, safe amount of radio-label (¹⁴C).

Frontage Clinical Services prioritizes the safety and well-being of our study participants, our employees, and visitors to our clinic. As such, we have incorporated additional policies and procedures, as recommended by the CDC.

Application for Clinical Research Study

(¹⁴C Study ) This is a Phase 1 study looking at how a new research medication called VT3989 moves through the body after a single oral dose that contains a small, safe amount of radio-label (¹⁴C).

Your information will be used solely for research recruitment purposes by our research team and will not be shared externally. All submissions are stored securely in accordance with HIPAA and Good Clinical Practice (GCP) standards.

Please fill out all required fields.